Helicobacter pylori infection

New England Journal of Medicine

Volumn 347, Issue 15, 2002, Pages 1175-1186

  Suerbaum, Sebastian ^a   Michetti, Pierre ^b,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH SALICYLATE; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; RANITIDINE BISMUTH CITRATE; TETRACYCLINE;

ATROPHY; BACTERIAL INFECTION; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DOSE RESPONSE; DUODENUM ULCER; ENDOSCOPIC BIOPSY; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROLOGY; STOMACH CARCINOMA; STOMACH LYMPHOMA; STOMACH ULCER; UREA BREATH TEST;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ORGANOMETALLIC COMPOUNDS; PROTON PUMPS; RANITIDINE; SALICYLATES; VIRULENCE;

EID: 0037057683     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra020542     Document Type: Review

References (107)

1. Feldman RA. Epidemiologic observations and open questions about disease and infection caused by Helicobacter pylori. In: Achtman M, Suerbaum S, eds. Helicobacter pylori: molecular and cellular biology. Wymondham, United Kingdom: Horizon Scientific Press, 2001:29-51.
2. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994;35:742-5.
3. Rowland M, Kumar D, Daly L, O'Connor P, Vaughan D, Drumm B. Low rates of Helicobacter pylori reinfection in children. Gastroenterology 1999;117:336-41.
4. Parsonnet J, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999;282:2240-5.
5. Goodman KJ, Correa P, Tengana Aux HJ, et al. Helicobacter pylori infection in the Colombian Andes: a population-based study of transmission pathways. Am J Epidemiol 1996;144:290-9.
6. Handt LK, Fox JG, Dewhirst FE, et al. Helicobacter pylori isolated from the domestic cat: public health implications. Infect Immun 1994;62:2367-74. [Erratum, Infect Immun 1995;63:1146.]
7. Dore MP, Sepulveda AR, El-Zimaity H, et al. Isolation of Helicobacter pylori from sheep - implications for transmission to humans. Am J Gastroenterol 2001;96:1396-401.
8. Tindberg Y, Blennow M, Granstrom M. Clinical symptoms and social factors in a cohort of children spontaneously clearing Helicobacter pylori infection. Acta Paediatr 1999;88:631-5.
9. Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and Helicobacter pylori. J Infect Dis 1993;168:219-21.
10. Rupnow MF, Shachter RD, Owens DK, Parsonnet J. A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States. Emerg Infect Dis 2000;6:228-37.
11. Solnick JV, Schauer DB. Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev 2001;14:59-97.
12. Morgner A, Lehn N, Andersen LP, et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000;118:821-8.
13. Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997;388:539-47. [Erratum, Nature 1997;389:412.]
14. Alm RA, Ling LS, Moir DT, et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Hdicobacter pylori. Nature 1999;397:176-80. [Erratum, Nature 1999;397:719.]
15. Falush D, Kraft C, Taylor NS, et al. Recombination and mutation during long-term gastric colonization by Helicobacter pylori: estimates of clock rates, recombination size, and minimal age. Proc Natl Acad Sci U S A 2001;98:15056-61.
16. Suerbaum S, Smith JM, Bapumia K, et al. Free recombination within Helicobacter pylori. Proc Natl Acad Sci U S A 1998;95:12619-24.
17. Mobley HLT. Helicobacter pylori urease. In: Achtman M, Suerbaum S, eds. Helicobacter pylori: molecular and cellular biology. Wymondham, United Kingdom: Horizon Scientific Press, 2001:155-70.
18. Weeks DL, Eskandari S, Scott DR, Sachs G. A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science 2000;287:482-5.
19. Josenhans C, Suerbaum S. Helicobacter motility and chemotaxis. In: Achtman M, Suerbaum S, eds. Helicobacter pylori: molecular and cellular biology. Wymondham, United Kingdom: Horizon Scientific Press, 2001:171-84.
20. Gerhard M, Hirmo S, Wadstrom T, et al. Helicobacter pylori, an adherent pain in the stomach. In: Achtman M, Suerbaum S, eds. Helicobacter pylori: molecular and cellular biology. Wymondham, United Kingdom: Horizon Scientific Press, 2001:185-206.
21. Ilver D, Arnqvist A, Ogren J, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998;279:373-7.
22. Guruge JL, Falk PG, Lorenz RG, et al. Epithelial attachment alters the outcome of Helicobacter pylori infection. Proc Natl Acad Sci U S A 1998;95:3925-30.
23. Montecucco C, Papini E, de Bernard M, et al. Helicobacter pylori VacA vacuolating cytotoxin and HP-Nap neutrophil activating protein. In: Achtman M, Suerbaum S, eds. Helicobacter pylori: molecular and cellular biology. Wymondham, United Kingdom: Horizon Scientific Press, 2001:245-63.
24. Szabo I, Brutsche S, Tombola F, et al. Formation of anion-selective channels in the cell plasma membrane by the toxin VacA of Helicobacter pylori is required for its biological activity. EMBO J 1999;18:5317-27.
25. Galmiche A, Rassow J, Doye A, et al. The N-terminal 34 kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release. EMBO J 2000;19:6361-70.
26. Salama NR, Otto G, Tompkins L, Falkow S. Vacuolating cytotoxin of Helicobacter pylori plays a role during colonization in a mouse model of infection. Infect Immun 2001;69:730-6.
27. Atherton JC, Peek RM Jr, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity, in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 1997;112:92-9.
28. Fischer W, Püls J, Buhrdorf R, Gebert B, Odenbreit S, Haas R. Systematic mutagenesis of the Helicobacter pylori cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8. Mol Microbiol 2001;42:1337-48.
29. Censini S, Lange C, Xiang Z, et al. cag, A pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 1996;93:14648-53.
30. Odenbreit S, Puls J, Sedlmaier B, Gerland E, Fischer W, Haas R. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 2000;287:1497-500.
31. Segal ED, Cha J, Lo J, Falkow S, Tompkins LS. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacterpylori. Proc Natl Acad Sci U S A 1999;96:14559-64.
32. Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002;295:683-6.
33. Dooley CP, Cohen H, Fitzgibbons PL, et al. Prevalence of Helicobatter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med 1989;321:1562-6.
34. Goodwin CS, Armstrong JA, Marshall BJ. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 1986;39:353-65.
35. Fan X, Gunasena H, Cheng Z, et al. Helicobacterpylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis. J Immunol 2000;165:1918-24.
36. Tufano MA, Rossano F, Catalanotti P, et al. Immunobiological activities of Helicobacter pylori porins. Infect Immun 1994;62:1392-9.
37. Mai UE, Perez-Perez GI, Allen JB, Wahl SM, Blaser MJ, Smith PD. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa. J Exp Med 1992;175:517-25.
38. Yamaoka Y, Kita M, Kodama T, Sawai N, Kashima K, Imanishi J. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut 1997;41:442-51.
39. Yamaoka Y, Kita M, Kodama T, Sawai N, Imanishi J. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996;110:1744-52.
40. Crabtree JE, Wyatt JI, Trejdosiewicz LK, et al. Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol 1994;47:61-6.
41. Crabtree JE, Shallcross TM, Heatley RV, Wyatt JI. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991;32:1473-7.
42. Naumann M, Wessler S, Bartsch C, et al. Activation of activator protein 1 and stress response kinases in epithelial cells colonized by Helicobacter pylori encoding the cag pathogenicity island. J Biol Chem 1999;274:31655-62.
43. - Helicobacter pylori. J Immunol 1999;163:5552-9.
44. Evans DJ Jr, Evans DG, Takemura T, et al. Characterization of a Helicobacter pylori neutrophil-activating protein. Infect Immun 1995;63:2213-20.
45. Perez-Perez GI, Dworkin BM, Chodos JE, Blaser MJ. Campylobacter pylori antibodies in humans. Ann Intern Med 1988;109:11-7.
46. Negrini R, Savio A, Appelmelk BJ. Autoantibodies to gastric mucosa in Helicobacter pylori infection. Helicobacter 1997;2:Suppl 1:S13-S16.
47. Harris PR, Smythies LE, Smith PD, Dubois A. Inflammatory cytokine mRNA expression during early and persistent Helicobacter pylori infection in nonhuman primates. J Infect Dis 2000;181:783-6.
48. Smythies LE, Waites KB, Lindsey JR, Harris PR, Ghiara P, Smith PD. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J Immunol 2000;165:1022-9.
49. Tomita T, Jackson AM, Hida N, et al. Expression of interleukin-18, a Th1 cytokine, in human gastric mucosa is increased in Helicobacter pylori infection. J Infect Dis 2001;183:620-7
50. Wang J, Brooks EG, Bamford KB, Denning TL, Pappo J, Ernst PB. Negative selection of T cells by Helicobacter pylori as a model for bacterial strain selection by immune evasion. J Immunol 2001;167:926-34.
51. Zhang QB, Nakashabendi IM, Mokhashi MS, Dawodu JB, Gemmell CG, Russell RI. Association of cytotoxin production and neutrophil activation by strains of Helicobacter pylori isolated from patients with peptic ulceration and chronic gastritis. Gut 1996;38:841-5.
52. Rudi J, Kuck D, Strand S, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest 1998;102:1506-14.
53. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402. [Erratum, Nature 2001;412:99.]
54. Dixon MF. Pathology of gastritis and peptic ulceration. In: Mobley HLT, Mendz GL, Hazell SL, eds. Helicobacter pylori: physiology and genetics. Washington, D.C.: ASM Press, 2001:459-69.
55. Schlemper RJ, van der Werf SD, Biemond I, Lamers CB. Seroepidemiology of gastritis in Japanese and Dutch male employees with and without ulcer disease. Eur J Gastroenterol Hepatol 1996;8:33-9.
56. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
57. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
58. Nomura A, Stemmermann GN, Chyou P-H, Karo I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-6.
59. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991;302:1302-5.
60. Fox JG. Helicobacter species and in vivo models of gastrointestinal cancer. Aliment Pharmacol Ther 1998;12:Suppl 1:37-60.
61. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
62. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639-42.
63. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-71.
64. Wotherspoon AC. Helicobacter pylori infection and gastric lymphoma. Br Med Bull 1998;54:79-85.
65. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995;345:1591-4.
66. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001;357:39-40.
67. Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997;89:1350-5.
68. McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869-74.
69. Blum AL, Talley NJ, O'Moráin C, et al, Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1875-81.
70. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2001;1:CD002096.
71. Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Aliment Pharmacol Ther 1998;12:735-40.
72. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6.
73. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001;357:1738-42. [Erratum, Lancet 2001;358:1734.]
74. Fox JG, Wang TC. Helicobacter pylori - not a good bug after all. N Engl J Med 2001;345:829-32.
75. Howden CW, Leontiadis GI. Extragastric manifestations of Helicobacter pylori - are they relevant? In: Hunt RH, Tytgat GN, eds. Helicobacter pylori: basic mechanisms to clinical cure 2000. Dordrecht, the Netherlands: Kluwer Academic, 2000:315-26.
76. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998;93:2330-8.
77. Drumm B, Koletzko S, Oderda G. Helicobacter pylori infection in children: a consensus statement. J Pediatr Gastroenterol Nutr 2000;30:207-13.
78. Graham DY, Qureshi WA. Markers of infection. In: Mobley HLT, Mendz GL, Hazell SL, eds. Helicobacter pylori: physiology and genetics. Washington, D.C.: ASM Press, 2001:499-510.
79. Bazzoli F. Key points from the revised Maastricht Consensus Report: the impact on general practice. Eur J Gastroenterol Hepatol 2001;13:Suppl 2:S3-S7.
80. Performance standards for antimicrobial susceptibility testing: ninth informational supplement. Wayne, Pa.: National Committee for Clinical Laboratory Standards, 1999.
81. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the Surveillance of H. pylori Antimicrobial Resistance Partnership (SHARP) study, 1993-1999. Ann Intern Med 2002;136:13-24.
82. Mégraud F, Hazell S, Glupczynski Y. Antibiotic susceptibility and resistance. In: Mobley HLT, Mendz GL, Hazell SL, eds. Helicobacter pylori: physiology and genetics. Washington, D.C.: ASM Press, 2001:511-30.
83. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996;1:138-44.
84. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248-53.
85. Malfertheiner P, Bayerdorffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999;13:703-12.
86. Zanten SJ, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999;13:289-95.
87. Misiewicz JJ, Harris AW, Bardhan KD, et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Gut 1997;41:735-9.
88. Catalano F, Branciforte G, Catanzaro R, et al. Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. Helicobacter 1999;4:178-84.
89. Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999;13:741-6.
90. Laine L, Fennerty MB, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 2000;95:3393-8.
91. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999;13:857-64.
92. Unge P. Antimicrobial treatment of H. pylori infection - a pooled efficacy analysis of eradication therapies. Eur J Surg Suppl 1998;582:16-26.
93. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:603-9.
94. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000;45:68-76.
95. Lee M, Kemp JA, Canning A, Egan C, Tataronis G, Farraye FA. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 1999;159:2312-6.
96. Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996;10:251-61.
97. Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week - a meta-analysis of efficacy. Aliment Pharmacol Ther 2000;14:1141-50.
98. Houben MH, Van Der Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-55.
99. Sung JJ, Chan FK, Wu JC, et al. One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. Aliment Pharmacol Ther 1999;13:1079-84.
100. Coelho LG, Leon-Barua R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Am J Gastroenterol 2000;95:2688-91.
101. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690-700.
102. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12.
103. Perri F, Festa V, Clemente R, et al. Randomized study of two "rescue" therapies for Helicobacterpylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.
104. Perri F, Villani MR, Quitadamo M, Annese V, Niro GA, Andriulli A. Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? Aliment Pharmacol Ther 2001;15:1017-22.
105. Delaney BC, Innes MA, Deeks J, et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2001;3:CD001961.
106. Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999;116:804-12.
107. Blanchard TG, Czinn SJ. Immunology of Helicobacter pylori and prospects for vaccine. Gastroenterol Clin North Am 2000;29:671-85.